MolecularHealth has announced an agreement with GATC Biotech, a global DNA sequencing service provider, under which GATC Biotech will provide protocols, support, and extensive training of MolecularHealth’s laboratory staff.
These contributions will complement MolecularHealth’s next-generation sequencing offerings and its proprietary TreatmentMAP oncology treatment decision support platform. Additionally, MolecularHealth will use GATC Biotech’s laboratory information management system in its newly opened clinical lab.
MolecularHealth employs advanced proprietary information technologies to sift through terabytes of genetic and molecular test findings in a fraction of the time needed for current manual analysis. The company provides doctors and patients with faster, more accurate insights into the role genes play in the progression and treatment of an individual’s cancer.
“In preparation for the launch of TreatmentMAP in Q1 of this year, it’s essential that we put the best protocols in place for our lab,” said Lloyd Everson, MD, CEO of MolecularHealth. “GATC Biotech has decades of experience in sequencing technology and services, and a standardized, validated, automated process. Their proven expertise will be invaluable to our team as we work to provide personalized, actionable information to cancer patients and their medical teams.”
“GATC Biotech is a global leader in genomic sequencing, and we are pleased to partner with MolecularHealth on this strategic collaboration to improve life for cancer patients,” said Peter Pohl, CEO of GATC Biotech. “We are convinced that our know-how, combined with MolecularHealth’s data interpretation, will pave the way for personalized medicine by enabling substantiated decisions about individual cancer care.”
A family-owned business, GATC Biotech is Europe’s leading service provider of DNA and RNA sequencing. For more than two decades, the company has offered sequencing and bioinformatics solutions from single samples up to large-scale projects. Its headquarters in Constance, Germany, houses its ISO 17025 certified genome and diagnostic center, with a focus on next- and third-generation sequencing.
Located in Houston metro area, MolecularHealth’s lab will offer two laboratory-developed tests: a targeted gene panel of more than 500 known cancer genes, and whole exome sequencing of the tumor genome. The company offers an end-to-end service that walks patients and their healthcare providers through the molecular diagnostic process—collecting tumor samples, analyzing the samples, and interpreting the results using a unique analytics platform—all to generate safer and more targeted cancer treatment choices.
As part of its offering, MolecularHealth will provide patients, oncologists, and pathologists with complete logistical support and help navigating insurance reimbursement for recommended treatments.
For more information, visit MolecularHealth and GATC Biotech.
